Iovance Biotherapeutics Inc. (IOVA)
Symbol Info
Listed Symbol IOVA
Name Iovance Biotherapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-1.27
Price Info
21 Day Moving Average $23.4033
21 Day EMA $22.530580
50 Day Moving Average $22.8324
50 Day EMA $21.700580
200 Day EMA $16.088780
200 Day Moving Average 13.615300
52 Week High $26.59
52 Week Low $7.26
52 Week Change $32.176700
Alpha 0.025439
Beta 1.9323
Standard Deviation 0.216365
R2 0.096019
Periods 60
Share Information
10 Day Average Volume 1,331,201
20 Day Average Volume 1,274,225
30 Day Average Volume 1,212,685
50 Day Average Volume 1,602,770
Outstanding Shares 123,830,506
Float Shares 102,808,844
Percent Float 83.02%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 303
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 6,999,474
Institute Holdings Percent -
Institute Sold Previous 3 Months 11,263,644
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 21,021,662
Price Change
7 Day Price Change $-1.289999
7 Day Percent Change -5.80%
21 Day Price Change $-3.9499989
21 Day Percent Change -15.86%
30 Day Price Change $-3.8899994
30 Day Percent Change -15.66%
Month To Date Price Change $-3.64
Month To Date Percent -14.80%
90 Day Price Change $5.670001
90 Day Percent Change 37.11%
Quarter To Date $-3.57
Quarter To Date Percent -14.56%
180 Day Price Change $10.620001
180 Day Percent Change 102.81%
200 Day Price Change $12.520000
200 Day Percent Change 148.52%
Year To Date $12.100000
Year To Date Percent 136.72%
Profile
Description Iovance Biotherapeutics Inc operates in the healthcare sector based in the United States. It is a pharmaceutical manufacturer attending to serious diseases such as cancer. The Company's lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. The TIL therapy involves growing a patient's special culture conditions outside the patient's body, or ex vivo, and then infusing the T cells back into the patient.
Details
Issue Type CS
Market Cap $2,594,249,101
Sec Type EQS
Auditor Marcum LLP
Total Shares Outstanding 123,830,506
CEO Maria Fardis
Employees 88
Last Audit UQ
Classification
CIK 0001425205
Industry Biotechnology
Sector Healthcare
NAICS Medicinal and Botanical Manufacturing(325411)
Info
Address 999 Skyway Road
Suite 150
San Carlos, CA 94070
Website https://www.iovance.com
Facisimile
Telephone +1 650 260-7120
Email sarah@sternir.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $2,087,036,730
Price To Sales -
Price To Free Cash -19.8
PE High Last 5 Years -
Price To Book 6.2
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 6.2
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 12.1
Leverage Ratio 1.1
Quick Ratio 11.9
Long Term Debt To Capital 0.01
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -41.88
Return On Equity -45.18
Return On Capital -43.6
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
IOVA
Iovance Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.